Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction

NCT04798430 · clinicaltrials.gov ↗

PHASE3

Phase

ENROLLING_BY_INVITATION

Status

2000

Enrollment

INDUSTRY

Sponsor class

Conditions

Cardiovascular Disease With Mention of Arteriosclerosis
Elevated Cholesterol
Familial Hypercholesterolemia

Interventions

DRUG: lerodalcibep

Sponsor

LIB Therapeutics LLC

Collaborators

[object Object]